Biotech/Medical Tech Stock News from Investorideas.com: Telemedicine and Weight Loss Stocks to Watch

Telemedicine and Weight Loss Stocks to Watch

Stocks Discussed: Integrated Ventures, Inc. (OTCQB: $INTV), Hims & Hers Health Inc. (NYSE: $HIMS), LifeMD, Inc. (Nasdaq: $LFMD), 23andMe Holding Co. (Nasdaq: $ME)

September 4, 2024 - Investorideas.com, a go-to investing platform covering health and wellness issues a snapshot looking at news and developments for the telemedicine and weight loss market, featuring new player in the market, Integrated Ventures, Inc. (OTCQB: INTV), a portfolio holdings company, focused on e-commerce technology, digital assets and consumer-focused investments.

According to Meticulous Research, the global telehealth market is set to experience significant growth, with an anticipated CAGR of 21.6% from 2022 to reach $539.73 billion by 2029. This robust expansion is primarily driven by several key factors, including the rising elderly population, the increasing incidence of chronic diseases, supportive government policies, and heightened awareness of telehealth benefits.

Research and Markets reports, “The United States Telehealth Market was valued at USD 21.11 Billion in 2023 and is expected to reach USD 35.58 Billion by 2030 with a CAGR 8.95%.”

Focusing on the growing trend of telemedicine and weight loss, Integrated Ventures, Inc. (OTCQB: INTV), just announced the formation and launch of their second, fully funded, 100% owned subsidiary - MedWellDirect, LLC, a Direct-To-Consumer (D2C) telemedicine solutions provider, mainly for weight loss and GLP-1 products as well as the acquisition of a 51% stake in GetTrim.Com™, owned by Healthy Lifestyle USA – an innovative telemedicine weight loss services provider.

Paid news dissemination for INTV

Read this article, featuring INTV in full at https://www.investorideas.com/news/2024/biotech/09041Telemedicine-and-Weight-Loss-Stocks.asp

This strategic move positions Integrated Ventures at the forefront of the rapidly expanding medical weight loss industry, which is experiencing significant growth driven by the increasing consumer adoption of new, weight loss medications such as Semaglutide and Tirzepatide.

Healthy Lifestyle USA has developed and launched two consumer-targeted platforms, GetTrim.Com and JoinTrim.Com, each offering unique and effective weight loss solutions, tailored to a wide audience. The dual-platform strategy, supported by advanced technological infrastructure and sophisticated marketing funnels, is designed to deliver accessible, effective and personalized weight loss services. By integrating cutting-edge telemedicine capabilities with a robust tech stack, Healthy Lifestyle USA, aims to create seamless, high-quality solutions and experiences for consumers, seeking safe and effective medical weight loss options.

The acquisition comes at a pivotal moment for the industry. Companies like Hims & Hers Health Inc., with a 3.2+ billion market cap, and Ro, have demonstrated the immense potential in this market, indicating a strong shift toward telemedicine-based weight loss solutions. The GetTrim and JoinTrim platform is trademarked and well-positioned to build on this success with its integrated telemedicine platforms for online consultations, real-time customer communication and secure transactions. By leveraging outsourced customer service models and third-party marketing funnels, the program is strategically designed to enhance user experience and achieve high conversion rates.

More from the news: Healthy Lifestyle USA’s platforms are built on a unified, cloud-based architecture that offers scalability, reliability, and security, compliant with HIPAA and GDPR regulations. Advanced reporting and analytics provide real-time insights into user behavior and treatment outcomes, utilizing machine-learning algorithms to enhance user experience and service delivery. The intuitive user interface ensures a seamless experience across all devices and telehealth features, further enhancing the comprehensive e-commerce functionalities.

Compliant with regulations to operate and provide medical consulting services in 49 states, including major markets like California, Florida, Texas, and New York, the GetTrim platform is well-positioned to reach a broad audience across the United States. This extensive reach aligns with Integrated Ventures' growth strategy to become a leading player in the medical weight loss sector.

More from the news Steve Rubakh, CEO of Integrated Ventures, Inc., commented, "The acquisition of GetTrim.Com is the engine to our multi-faceted B2C/D2C growth strategy and reinforces our commitment to investing in high-growth sectors. The GetTrim program, with its dual-platform approach and cutting-edge technology, is uniquely positioned to address the growing consumer demand for medical weight loss solutions like Semaglutide and Tirzepatide. We are excited to work closely with the Healthy Lifestyle USA team to scale these platforms, enhance user experience, and drive long-term shareholder value. Note that additional details related to this transactions are available via 8K, filed with SEC."

Showing the growth potential of the sector, Hims & Hers Health Inc. (NYSE: HIMS), the leading health and wellness platform, on August 5^th announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com.

"Our second quarter results mark an acceleration in what was already an incredible trajectory. During the quarter, subscribers on our platform approached 1.9 million, increasing 43% year-over-year," said Andrew Dudum, co-founder and CEO. "We believe access to life-changing solutions should be simple, convenient, affordable, and designed for the individual. As we expand the capabilities on our platform, we are only more convinced that we can help an individual in every household in the country feel great."

From the news: Yemi Okupe, CFO, stated, "An approach to democratizing access to high-quality personalized solutions on our platform at an affordable price continues to resonate with consumers. We are seeing this improve our ability to attract new users to longer-tenured specialties, while also allowing us to more rapidly scale new specialties. During the second quarter, these dynamics drove an acceleration in revenue growth and record profitability levels. We are updating our full year outlook to reflect this improving momentum and continue to believe we are on a clear path toward serving tens of millions of customers as we scale this increasingly powerful and efficient model."

On August 7^th, LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, reported financial results for the three and six months ended June 30, 2024.

From the news: Management Commentary

“LifeMD’s core telehealth business had a very strong quarter, led by continued outperformance in our GLP-1 weight management offering. Telehealth revenue increased 67% over the prior year and our patient subscriber base grew to approximately 254,000 by quarter end. Importantly, our telehealth business became profitable on an adjusted EBITDA basis, one quarter ahead of guidance,” said Justin Schreiber, Chairman and CEO of LifeMD. “The demand we continue to generate for our virtual care services and pharmacy offerings is indicative of the significant market opportunity that exists for the convenient and affordable access to high-quality healthcare our telehealth platform and affiliated medical group offers. What we continue to demonstrate, quarter over quarter, is that we have a sustainable and now profitable business that is well positioned to leverage the transformational shift that is occurring in how consumers access healthcare.”

“WorkSimpli’s performance during the quarter was pressured by an unexpectedly challenging advertising environment for its products and executional issues, which have since been addressed by their leadership. Based on its current operational performance and following recent strategic efforts, we expect WorkSimpli’s financial results to improve in the second half of the year, and to return to peak profitability by year-end 2024 on a monthly run-rate basis with significant growth in 2025. While we remain confident in our ability to monetize this non-core asset, we expect our core telehealth business will be the driving force of long-term growth in revenue and profitability,” he added.

“We are extremely pleased with the performance of our telehealth business, which led to positive net cash flow for LifeMD on a consolidated basis. On a standalone basis, this business posted cash flow from operations of approximately $3 million for the quarter and generated positive adjusted EBITDA,” commented Marc Benathen, Chief Financial Officer of LifeMD. “Our core telehealth business’ performance continues to be ahead of expectations and, as such, we are raising our 2024 telehealth revenue guidance to $150 million from $140 million previously and are introducing adjusted EBITDA guidance for telehealth of $3 to $4 million, both ahead of previous expectations. Despite the outperformance of telehealth, due to WorkSimpli’s first half results we are revising 2024 consolidated adjusted EBITDA guidance to $13 million to $15 million, with no change to consolidated revenue guidance. We remain bullish on the consolidated business led by our core telehealth platform, which remains well positioned as the long-term growth driver.”

On August 28^th, Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, announced it is now offering Ozempic®, Wegovy® and compounded semaglutide through a weight loss program on its telehealth platform, providing consumers with access to affordable weight management care through a convenient subscription-based model.

If prescribed, Lemonaid Health patients will now have access to once-weekly injectable GLP-1 medication offerings through an accessible monthly membership subscription that includes clinician consultations (via video or phone), a GLP-1 prescription (additional cost), ongoing care and support, as well as an annual lab order (as needed).

“We are excited to be helping our customers get access to potentially life changing weight management programs and GLP-1 medication through Lemonaid Health and 23andMe,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “We are focused on helping customers live healthier, longer lives and believe weight management is an important pillar. We also remain enthusiastic as we see encouraging research come out about additional applications for GLP-1s and ways they may be able to prevent or mitigate disease.”

From the news: After an initial consultation with a clinician to confirm eligibility and medication preference, the membership is $49 per month with no long-term commitment required, and transparent medication pricing that doesn’t change based on dosage amount. Medication is charged separately starting at $299 a month for compounded semaglutide. Lemonaid provides fast shipping directly to patients, and purchases may be eligible for payment via HSA and FSA programs.

Marketdata estimates that the market for telehealth weight loss services was worth $6.9 billion in 2023. Revenues are forecast to grow 8.2% in 2024, and 7.5% annually to 2028.

Continued: The average weight loss telehealth service user has 5 follow-up visits per year, at a cost of $50 per visit. Monthly subscription fees cost $30-80, so the average user spends about $610 per year, not including the cost of the medications. This estimate is likely conservative.

Telehealth and weight loss appear to be a perfect marriage for growth for the stocks capitalizing on this trend based on recent earning reports from some of the key players, but as always, there are winners and losers in every sector and investors need to do their due diligence.

Research and find more biotech and telemedicine stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

About Investorideas.com

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.

Disclaimer/Disclosure: This news article featuring - Integrated Ventures, Inc. (OTCQB: INTV) is a paid for news release creation and dissemination on Investorideas.com. Our site does not make recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Privacy policy: https://www.investorideas.com/About/Private_Policy.asp